[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-myeloid-leukemia---chronic-phase\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-myeloid-leukemia---chronic-phase":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642928",false,"NCT07640750","Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines","Retrospective and Prospective Observational Study on the Efficacy and Tolerability of Asciminib in Real-world Clinical Practice in Patients With Chronic Myeloid Leukemia Treated in Second or Subsequent Lines: ASCIRLI (ASCIminib in Real-Life Italy)","ASCIRLI","Inclusion Criteria:\n\n1. Patients aged ≥ 18 years and no upper age limit;\n2. Patients with a diagnosis of CML-CP who started treatment with asciminib according to clinical practice - from the date of commercial availability of asciminib - until the end of recruitment period (two years after the first patient included);\n3. Patients treated with asciminib in second or subsequent lines of therapy (≥2L)\n4. Patients who provide written informed consent to participate in the study (if applicable).\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines. The main object of the study is to assess the achievement of Major Molecular Response.",[24,25],"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia - Chronic Phase",[27,28,29,30],"chronic myeloid leukemia","asciminib","real-life","second line","NOT_YET_RECRUITING","2026-06-08",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":20},"2026-09-01",{"date":39,"type":20},"2031-12-01",{"name":41,"class":42},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",""]